Supreme Court Rejects Appeals From R. Kelly and 'Pharma Bro' Martin Shkreli
The U.S. Supreme Court on Monday rejected appeals from two high-profile figures: R&B singer R. Kelly, and former pharmaceutical executive Martin Shkreli, known as "Pharma Bro." Kelly, who is serving a 20-year prison sentence,
Supreme Court rejects Martin Shkreli fine appeal
The Supreme Court on Monday rejected a bid by notorious 'pharma bro' Martin Shkreli to hear his appeal of a $64 million financial penalty on the fraudster. Shkreli had been ordered to pay that penalty for blocking competition to a life-saving drug whose price he had raised by more than $700 per pill.
Supreme Court Snubs Martin Shkreli’s Last-Ditch Bid to Avoid $64 Million Fine
There were no generic alternatives to a lifesaving drug when Shkreli jacked up its price by more than $700 per pill in 2015.
Martin Shkreli can't escape his $64 million fine
The U.S. Supreme Court decided on Monday not to take up Martin Shkreli’s appeal of a $64.6 million penalty he received after raising the price of a lifesaving drug by more than 4,000% during his time as a pharma CEO.
Supreme Court rejects ‘Pharma Bro’ Martin Shkreli’s appeal of $65M in penalties
The judge cited Shkreli’s “particularly heartless and coercive” tactics in monopolizing Daraprim and keeping generic rivals off the market.
US Supreme Court rejects 'Pharma Bro' Martin Shkreli's appeal of penalties
The U.S. Supreme Court declined on Monday to hear former pharmaceutical company CEO Martin Shkreli's challenge to a $64.6 million financial penalty imposed by a judge after he
Pfizer Stock Rises After It Gets an Activist. What Starboard’s Track Record With Pharma Tells Us.
Starboard has approached two former Pfizer executives, Ian Read and Frank D’Amelio, to assist in its efforts, and they have ...
MM&M1h
Skyrizi notches top pharma, Rx brand spot for Q3 2024
Skyrizi had an estimated national TV ad spend of $93.7 million — the highest amount of any brand in the top 10 during this ...
Supreme Court rejects appeal from ‘Pharma Bro’ Martin Shkreli
The Supreme Court on Monday rejected an appeal from Martin Shkreli, who was once dubbed “Pharma Bro” after jacking up the ...
FiercePharma7h
Dupixent takes pharma DTC top spot as Pfizer's COVID drug Paxlovid makes a comeback
AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...
The US wants to cut its reliance on Chinese pharma. These stocks could benefit.
On 9 September the US House of Representatives passed the draft of the Biosecure Act, which aims to prohibit US pharma ...
Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma
Kirk Spano and Bhavneesh Sharma talk biotech, pharma, and why complete response letters are a good contrarian buying ...
Richmond BizSense15h
Richmond-based pharma company Kaleo laying off dozens of employees
The company described the move as a “mass layoff of its sales representatives and related employees across the country,” ...
India’s Piramal Pharma Aims to Double Revenue in Five Years
Piramal Pharma Ltd. expects new molecule development and an $80 million expansion of its sterile injectable facility in ...
Pharmabiz13h
Indian pharma supply chain opts for ERP to accelerate efficiency in track & trace systems to facilitate compliance
India’s pharmaceutical supply chain is amongst the most complex supply networks. This is because a big company can operate at the national level with 8,000-10,000 distributors who individually sell ...
MM&M3d
Real Chemistry strikes partnership with Corval, aiming to tackle biggest challenges in pharma commercialization
The partnership will combine Real Chemistry’s consultative and strategic expertise with Corval’s commercialization planning ...
FiercePharma3d
Fierce Pharma Asia—Roche's $850M-plus deal with Regor; Legend's busy week; WuXi asset sales?
On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American ...
Kamala Harris should prosecute Big Pharma, not bail it out
Department of Justice is arguing that any company working for government can seize whatever patents it wants. That goes ...